Keypoint of Antifungal Application for ECMO Supported COVID-19 Patients

Extracorporeal membrane oxygenation is currently the most powerful means of respiratory/cardiac support for COVID-19 patients. The critically ill patients with COVID-19 have a longer time of disease course and may be treated with cocorticoids in the early stage. Cellular immunosuppression may occur in many patients, especially those who need to be admitted to the ICU for mechanical ventilation. The fungal infection of these patients in the later stages is worthy of attention. This article discussed the overview of ECMO, PK/PD of antifungal drugs and keypoint of application. Provided a reference for the individualized drug treatment of patients with secondary fungal infection in the late COVID-19.